Guardant Health, Inc.

NasdaqGS:GH Rapport sur les actions

Capitalisation boursière : US$3.8b

Guardant Health Croissance future

Future contrôle des critères 1/6

Guardant Health devrait augmenter ses bénéfices et son chiffre d'affaires de 24.9% et de 17% par an respectivement. Le BPA devrait croître de de 27.5% par an. Le rendement des capitaux propres devrait être -216.4% dans 3 ans.

Informations clés

24.9%

Taux de croissance des bénéfices

27.5%

Taux de croissance du BPA

Healthcare croissance des bénéfices20.9%
Taux de croissance des recettes17.0%
Rendement futur des capitaux propres-216.4%
Couverture par les analystes

Good

Dernière mise à jour18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

Nov 08
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Oct 25
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 24
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31
Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12
Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04
Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14
Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Nov 20
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 26
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Sep 05
A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Aug 15
Is Guardant Health (NASDAQ:GH) A Risky Investment?

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

May 28
A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Apr 05
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Dec 28
Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:GH - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20261,021-324-227-14016
12/31/2025848-377-264-18622
12/31/2024724-415-296-23922
9/30/2024692-512-274-254N/A
6/30/2024644-491-299-281N/A
3/31/2024604-461-301-281N/A
12/31/2023564-479-345-325N/A
9/30/2023536-432-363-337N/A
6/30/2023510-508-383-337N/A
3/31/2023482-665-418-355N/A
12/31/2022450-655-387-309N/A
9/30/2022431-606-388-296N/A
6/30/2022408-551-363-271N/A
3/31/2022391-419-309-221N/A
12/31/2021374-406-284-209N/A
9/30/2021344-409-249-191N/A
6/30/2021324-379-191-146N/A
3/31/2021298-336-143-107N/A
12/31/2020287-254-158-104N/A
9/30/2020271-185-129-75N/A
6/30/2020258-120-118-66N/A
3/31/2020245-77-102-56N/A
12/31/2019214-76-68-47N/A
9/30/2019184-76-60-43N/A
6/30/2019145-87-81-67N/A
3/31/2019111-97-89-70N/A
12/31/201891-85-92-72N/A
9/30/201878-75-85-64N/A
6/30/201867-84N/A-68N/A
3/31/201857-83N/A-65N/A
12/31/201750-89N/A-72N/A
12/31/201625-46N/A-37N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: GH devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: GH devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: GH devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de GH ( 17% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de GH ( 17% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: GH devrait être non rentable dans 3 ans.


Découvrir les entreprises en croissance